JP2007506417A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506417A5
JP2007506417A5 JP2006527354A JP2006527354A JP2007506417A5 JP 2007506417 A5 JP2007506417 A5 JP 2007506417A5 JP 2006527354 A JP2006527354 A JP 2006527354A JP 2006527354 A JP2006527354 A JP 2006527354A JP 2007506417 A5 JP2007506417 A5 JP 2007506417A5
Authority
JP
Japan
Prior art keywords
nucleic acid
tumor
associated antigen
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006527354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506417A (ja
JP5144933B2 (ja
Filing date
Publication date
Priority claimed from DE10344799A external-priority patent/DE10344799A1/de
Application filed filed Critical
Publication of JP2007506417A publication Critical patent/JP2007506417A/ja
Publication of JP2007506417A5 publication Critical patent/JP2007506417A5/ja
Application granted granted Critical
Publication of JP5144933B2 publication Critical patent/JP5144933B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006527354A 2003-09-26 2004-09-23 診断および治療のための腫瘍関連細胞表面抗原の同定 Expired - Lifetime JP5144933B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10344799A DE10344799A1 (de) 2003-09-26 2003-09-26 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE10344799.7 2003-09-26
PCT/EP2004/010697 WO2005030250A2 (de) 2003-09-26 2004-09-23 Identifizierung von tumorassoziierten zelloberflächen-antigenen für die diagnose und therapie

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011253535A Division JP5639989B2 (ja) 2003-09-26 2011-11-21 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2012223869A Division JP5804519B2 (ja) 2003-09-26 2012-10-09 診断および治療のための腫瘍関連細胞表面抗原の同定

Publications (3)

Publication Number Publication Date
JP2007506417A JP2007506417A (ja) 2007-03-22
JP2007506417A5 true JP2007506417A5 (enExample) 2007-11-08
JP5144933B2 JP5144933B2 (ja) 2013-02-13

Family

ID=34306102

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006527354A Expired - Lifetime JP5144933B2 (ja) 2003-09-26 2004-09-23 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2011253535A Expired - Lifetime JP5639989B2 (ja) 2003-09-26 2011-11-21 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2012223869A Expired - Lifetime JP5804519B2 (ja) 2003-09-26 2012-10-09 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2014113690A Expired - Lifetime JP5969538B2 (ja) 2003-09-26 2014-06-02 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2016094337A Expired - Lifetime JP6196350B2 (ja) 2003-09-26 2016-05-10 診断および治療のための腫瘍関連細胞表面抗原の同定

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011253535A Expired - Lifetime JP5639989B2 (ja) 2003-09-26 2011-11-21 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2012223869A Expired - Lifetime JP5804519B2 (ja) 2003-09-26 2012-10-09 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2014113690A Expired - Lifetime JP5969538B2 (ja) 2003-09-26 2014-06-02 診断および治療のための腫瘍関連細胞表面抗原の同定
JP2016094337A Expired - Lifetime JP6196350B2 (ja) 2003-09-26 2016-05-10 診断および治療のための腫瘍関連細胞表面抗原の同定

Country Status (8)

Country Link
US (6) US7875424B2 (enExample)
EP (22) EP2266612B1 (enExample)
JP (5) JP5144933B2 (enExample)
AU (1) AU2004275500B2 (enExample)
CA (4) CA2539837C (enExample)
DE (1) DE10344799A1 (enExample)
ES (1) ES2634705T3 (enExample)
WO (1) WO2005030250A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2005030955A1 (ja) * 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Nk細胞に発現するタンパク質
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP2009502112A (ja) * 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 腎細胞癌を診断および処置するための方法
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2007098093A2 (en) * 2006-02-17 2007-08-30 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN104971341B (zh) 2008-10-27 2019-12-13 北海道公立大学法人札幌医科大学 肿瘤干细胞分子标记
US20120322075A1 (en) 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
EP2493917B8 (en) * 2009-10-26 2020-03-04 Externautics S.P.A. Breast tumor markers and methods of use thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
US20130022983A1 (en) 2009-10-26 2013-01-24 Externautics S.P.A. Colon and Rectal Tumor Markers and Methods of Use Thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
FR2973380B1 (fr) * 2011-04-01 2018-02-09 C.Ris Pharma Peptides isoles et purifies a partir de testicules de roussette
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
TW201302800A (zh) * 2011-06-10 2013-01-16 腫瘤療法 科學股份有限公司 Ｓｅｍａ５ｂ胜肽及含其之疫苗
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
SG11201503918XA (en) * 2012-12-04 2015-06-29 Oncotherapy Science Inc Sema5b peptides and vaccines containing the same
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック， インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US20200040103A1 (en) * 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2023129460A2 (en) * 2021-12-27 2023-07-06 Memorial Sloan-Kettering Cancer Center Tumor mhc class i expression is associated with interleukin-2 response in melanoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
AU7516494A (en) * 1993-07-29 1995-02-28 Isis Pharmaceuticals, Inc. Oligomers for modulating human immunodeficiency virus
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
SE508004C2 (sv) 1996-08-07 1998-08-10 Intermec Ptc Ab Arrangemang för automatisk inställning av printrar samt material därtill
WO1998037094A2 (en) * 1997-02-24 1998-08-27 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998055508A2 (en) * 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
AU764441B2 (en) * 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
WO2000037491A2 (en) * 1998-12-22 2000-06-29 Genset Dnas encoding proteins with signal sequences
CA2368098A1 (en) * 1999-06-25 2001-01-04 Genset S.A. Complementary dna's encoding proteins with signal peptides
CA2393616A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2001077292A2 (en) * 2000-04-07 2001-10-18 Senomyx, Inc. Novel signal transduction molecules
CA2408134A1 (en) * 2000-05-18 2001-11-22 Incyte Genomics, Inc. G-protein coupled receptors
JP2002112793A (ja) * 2000-08-04 2002-04-16 Japan Science & Technology Corp 新規ｇ蛋白質共役受容体
AU2001288237A1 (en) * 2000-08-07 2002-02-18 Curagen Corporation Proteins and nucleic acids encoding g-protein coupled receptors
EP1326973A2 (en) * 2000-10-04 2003-07-16 Bayer Aktiengesellschaft Regulation of human gpcr-like protein
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
WO2003025148A2 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR20050008644A (ko) * 2001-12-21 2005-01-21 엘지 바이오메디컬 인스티튜트 위암에서의 유전자 발현 프로파일
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030170639A1 (en) * 2002-03-11 2003-09-11 Youmin Shu Liver transmembrane protein gene
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005021793A1 (en) * 2003-08-29 2005-03-10 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

Similar Documents

Publication Publication Date Title
JP2007506417A5 (enExample)
JP2008537546A5 (enExample)
JP2007537197A5 (enExample)
JP2006516190A5 (enExample)
JP2010047597A5 (enExample)
US7642239B2 (en) Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
RU2008114318A (ru) Идентификация опухолевых антигенов для диагностики и терапии
US20070112179A1 (en) Novel compounds
EP2682475A1 (en) Antibody and antigen recognizing tumor-initiating cells and use thereof
CN102325548A (zh) 用于癌症的诊断和治疗的方法和组合物
EA001398B1 (ru) ПОСЛЕДОВАТЕЛЬНОСТЬ кДНК , КОДИРУЮЩАЯ ПОЛИПЕПТИД МАММАГЛОБИНА, И ЕЁ ПРОИЗВОДНОЕ, ПОЛИПЕПТИД МАММАГЛОБИНА, СПОСОБЫ ДИАГНОСТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ И НАБОРЫ ДЛЯ ОСУЩЕСТВЛЕНИЯ СПОСОБОВ
CN107028969A (zh) 用于癌症诊断和治疗的方法和组合物
JP2005519608A5 (enExample)
JP2007526759A5 (enExample)
JP2001522238A (ja) 胃腸管の疾患の検出に有用な試薬および方法
JP2008527998A (ja) Ｎｓｃｌｃの診断のためのｇｉｔｒ抗体
JP2003521244A5 (enExample)
US20070269452A1 (en) Methods and compositions for the diagnosis and treatment of cancer
JP2001526546A (ja) 肺の疾患の検出に有用な試薬および方法
CN108329387B (zh) 癌症相关的肿瘤特异转录本lin28b-tst及其用途
US20220363767A1 (en) Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targets
JP2012525121A5 (enExample)
CN101161283B (zh) CMTM1-v17的新应用及其拮抗剂
JP2012525121A (ja) 診断および治療のための腫瘍関連マーカーの同定
US7641902B2 (en) Compositions and methods for detecting cancer and for inhibiting metastasis